Serendipity Biopharma (LQDA) reports 25,000-share 10b5-1 sale on 04/09/2026

Rhea-AI Filing Summary

Serendipity Biopharma LLC filed a Rule 144 notice reporting resale activity in common stock. The filing lists 10b5-1 sales: 25,000 shares sold on 04/09/2026 for $1,002,887.50 and an earlier sale of 66,610 shares on 01/12/2026 for $2,493,212.30. The broker listed is Morgan Stanley Smith Barney LLC and the filing references NASDAQ.

Insights

Securities Compliance Analyst

Routine Rule 144 resale notices tied to 10b5-1 plans were reported; filings list exact sale dates and amounts.

The filing records resale transactions executed under a 10b5-1 arrangement: $1,002,887.50 for 25,000 shares on 04/09/2026 and $2,493,212.30 for 66,610 shares on 01/12/2026. Broker details include Morgan Stanley Smith Barney LLC.

These notices document reported dispositions rather than corporate actions; cash‑flow treatment and holder identities beyond Serendipity Biopharma LLC (and an associated name, Roger A. Jeffs) are as stated in the excerpt. Subsequent filings would show further resale activity if any.

Key Figures

Sale on 04/09/2026: 25,000 shares Proceeds on 04/09/2026: $1,002,887.50 Sale on 01/12/2026: 66,610 shares +1 more

4 metrics

Sale on 04/09/2026 25,000 shares 10b5-1 sale reported at <date>04/09/2026</date>

Proceeds on 04/09/2026 <money>$1,002,887.50</money> Amount received for 25,000 shares on <date>04/09/2026</date>

Sale on 01/12/2026 66,610 shares 10b5-1 sale reported at <date>01/12/2026</date>

Proceeds on 01/12/2026 <money>$2,493,212.30</money> Amount received for 66,610 shares on <date>01/12/2026</date>

Key Terms

10b5-1, Rule 144, Form 144

3 terms

10b5-1 regulatory

"10b5-1 Sales for SERENDIPITY BIOPHARMA LLC/ROGER A JEFFS"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Rule 144 regulatory

"Filer Information | 144: Filer Information"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Form 144 regulatory

"CONTENT METADATA: "form_type": "144""

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	1008000.00	88114429	04/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/18/2020	Merger or Acquisition	Issuer			25000	11/18/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SERENDIPITY BIOPHARMA LLCC/O ROGER A JEFFS 419 Davis Drive, Suite 100 Morrisville NC 27560	Common	04/09/2026	25000	1002887.50
SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100 Morrisville NC 27560	Common	01/12/2026	66610	2493212.30

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the LQDA Form 144 filing disclose?

It discloses resale notices under Rule 144 for common stock. The filing lists 10b5-1 sales of 25,000 shares on 04/09/2026 for $1,002,887.50 and 66,610 shares on 01/12/2026 for $2,493,212.30 and names the broker.

Who executed the sales reported in the LQDA filing?

Sales are attributed to Serendipity Biopharma LLC (and related reporting name Roger A. Jeffs). The excerpt shows those entities with addresses and identifies the transactions as 10b5-1 sales.

Were the sales executed under a trading plan?

Yes — the excerpt identifies the transactions as 10b5-1 sales. That indicates they were executed under pre-established plans; exact plan terms are not included in the excerpt.

Which broker is listed in the Form 144 for LQDA?

Morgan Stanley Smith Barney LLC is listed as the broker. The filing includes a broker address and references NASDAQ in the securities information.

What were the dollar amounts reported for the disclosed sales?

The filing lists $1,002,887.50 for 25,000 shares and $2,493,212.30 for 66,610 shares. Each amount is tied to the specific sale date shown in the excerpt.